Yuebing Li

Nov 14, 2023 | neurologylive.com | Yuebing Li

WATCH TIME: 5 minutes“This treatment has been approved by the FDA for patients with generalized myasthenia gravis who test positive for the receptor antibody. Therefore, this specific patient population is well-suited for this alternative. It's important to note that this is a subcutaneous continuous form, not an intravenous one, and should be administered by a healthcare provider, not the patient.

Aug 1, 2023 | n.neurology.org | Yuebing Li |Devon A. Cohen |John Daniel Bireley |Joshua Santucci

REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.